Avience Biomedicals IPO

About this issue

Avience Biomedicals listed at +90.0% against its issue price of ₹208. The book is 385.32 times subscribed overall. The grey market premium is +₹145 (+69.7%), which is an informal figure and not a quoted price. Our call is Risky, on 75% of our checks.

Segment

SME

Price

₹208

Lot size

600 shares

One lot costs

₹1,24,800

Issue size

₹29 Cr

Grey market premium

+₹145 (+69.7%)

Subscribed

385.32x

Listed at

+90.0%

Our call

Risky

What we checked

• Profitable in the latest yearPAT ₹5.74 Cr
• Profit grew year on yearPAT -21%
• Revenue grew year on yearRevenue -9%
• Borrowing under half of net worthDebt/net worth 0.94
• Return on net worth above 15%RoNW 49.9%
• Post-issue P/E under 40P/E 16.6
• Price to book under 6P/B 3.7
• Majority is fresh capital100% fresh issue
• Promoters keep at least half64.6% held post-issue
• Anchor investors participatedAnchor book placed
• Overall book more than 10× covered385.3× overall

4 further checks could not be judged, because the issue did not disclose enough. They count neither for nor against.